ANVISA guidelines for two-stage design [Two-Stage / GS Designs]

posted by Helmut Homepage – Vienna, Austria, 2020-02-12 13:12 (711 d 22:03 ago) – Posting: # 21164
Views: 4,713

Hi ElMaestro,

» » ignorance of the intra-individual variability of the drug;
»
»
» Ermmm...... WHAT???? :-D:party:

Lost in translation?

É aceitável usar uma abordagem de dois estágios para demonstrar a bioequivalência baseada nodesconhecimento da variabilidade do fármaco;


I have the same translation like Mauricio. Google-translate suggests ‘unknowing’ for ‘nodesconhecimento’ but if you feed the entire sentence, ‘ignorance’ shows up. :-D

Dif-tor heh smusma 🖖
Helmut Schütz
[image]

The quality of responses received is directly proportional to the quality of the question asked. 🚮
Science Quotes

Complete thread:

Activity
 Admin contact
21,848 posts in 4,572 threads, 1,555 registered users;
online 4 (0 registered, 4 guests [including 3 identified bots]).
Forum time: Monday 11:15 CET (Europe/Vienna)

Do, or do not.
There is no ‘try’.    Yoda

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5